Ventana PD-L1 regulatory update

FDA approved Roche’s Ventana PD-L1 (SP142) Assay as a complementary diagnostic to provide PD-L1 status on patients who are considering treatment with Tecentriq atezolizumab for metastatic urothelial cancer. FDA concurrently granted accelerated approval to Tecentriq, a human mAb against PD-L1, from Roche’s Genentech Inc. unit. ...